Brandywine Global Investment Management LLC Buys Shares of 185,976 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Brandywine Global Investment Management LLC bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 4th quarter, HoldingsChannel.com reports. The fund bought 185,976 shares of the biotechnology company’s stock, valued at approximately $22,613,000.

A number of other institutional investors and hedge funds have also recently made changes to their positions in SRPT. Manchester Capital Management LLC boosted its holdings in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 110 shares in the last quarter. MassMutual Private Wealth & Trust FSB raised its position in Sarepta Therapeutics by 169.6% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 156 shares during the last quarter. Sunbelt Securities Inc. boosted its stake in shares of Sarepta Therapeutics by 446.2% during the third quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 232 shares in the last quarter. Newbridge Financial Services Group Inc. bought a new stake in shares of Sarepta Therapeutics during the fourth quarter worth about $36,000. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after buying an additional 194 shares during the period. Institutional investors own 86.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Needham & Company LLC reissued a “buy” rating and set a $202.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, March 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $163.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. Royal Bank of Canada lowered their target price on Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a research report on Thursday, February 27th. HC Wainwright reiterated a “sell” rating and issued a $75.00 price target on shares of Sarepta Therapeutics in a research report on Wednesday, March 19th. Finally, Scotiabank lowered their price objective on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating for the company in a research report on Thursday, March 20th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $167.41.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 7.70% of the company’s stock.

Sarepta Therapeutics Price Performance

SRPT stock opened at $70.41 on Monday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The company’s 50-day moving average is $102.66 and its 200-day moving average is $115.90. The stock has a market capitalization of $6.83 billion, a PE ratio of 56.33 and a beta of 0.79. Sarepta Therapeutics, Inc. has a 1 year low of $67.88 and a 1 year high of $173.25.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.